34 related articles for article (PubMed ID: 12531651)
1. Intranasal immunization of mice with chimera of Salmonella Typhi protein elicits protective intestinal immunity.
Chakraborty S; Dutta P; Pal A; Chakraborty S; Banik G; Halder P; Gope A; Miyoshi SI; Das S
NPJ Vaccines; 2024 Feb; 9(1):24. PubMed ID: 38321067
[TBL] [Abstract][Full Text] [Related]
2. Phosphoproteomics analysis of male and female Schistosoma mekongi adult worms.
Simanon N; Adisakwattana P; Thiangtrongjit T; Limpanont Y; Chusongsang P; Chusongsang Y; Anuntakarun S; Payungporn S; Ampawong S; Reamtong O
Sci Rep; 2019 Jul; 9(1):10012. PubMed ID: 31292487
[TBL] [Abstract][Full Text] [Related]
3. Treatment with P28GST, a schistosome-derived enzyme, after acute colitis induction in mice: Decrease of intestinal inflammation associated with a down regulation of Th1/Th17 responses.
Sarazin A; Dendooven A; Delbeke M; Gatault S; Pagny A; Standaert A; Rousseaux C; Desreumaux P; Dubuquoy L; Capron M
PLoS One; 2018; 13(12):e0209681. PubMed ID: 30592734
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of the rSh28GST urinary schistosomiasis vaccine: A phase 3 randomized, controlled trial in Senegalese children.
Riveau G; Schacht AM; Dompnier JP; Deplanque D; Seck M; Waucquier N; Senghor S; Delcroix-Genete D; Hermann E; Idris-Khodja N; Levy-Marchal C; Capron M; Capron A
PLoS Negl Trop Dis; 2018 Dec; 12(12):e0006968. PubMed ID: 30532268
[TBL] [Abstract][Full Text] [Related]
5. Receptor Binding by Cholera Toxin B-Subunit and Amino Acid Modification Improves Minimal Peptide Immunogenicity.
Boberg A; Stålnacke A; Bråve A; Hinkula J; Wahren B; Carlin N
ISRN Mol Biol; 2012; 2012():170676. PubMed ID: 27335661
[TBL] [Abstract][Full Text] [Related]
6. The schistosome glutathione S-transferase P28GST, a unique helminth protein, prevents intestinal inflammation in experimental colitis through a Th2-type response with mucosal eosinophils.
Driss V; El Nady M; Delbeke M; Rousseaux C; Dubuquoy C; Sarazin A; Gatault S; Dendooven A; Riveau G; Colombel JF; Desreumaux P; Dubuquoy L; Capron M
Mucosal Immunol; 2016 Mar; 9(2):322-35. PubMed ID: 26174763
[TBL] [Abstract][Full Text] [Related]
7. Protective immunity against Naegleria fowleri infection on mice immunized with the rNfa1 protein using mucosal adjuvants.
Lee J; Yoo JK; Sohn HJ; Kang HK; Kim D; Shin HJ; Kim JH
Parasitol Res; 2015 Apr; 114(4):1377-85. PubMed ID: 25604672
[TBL] [Abstract][Full Text] [Related]
8. Immunization with the recombinant Cholera toxin B fused to Fimbria 2 protein protects against Bordetella pertussis infection.
Olivera N; Castuma CE; Hozbor D; Gaillard ME; Rumbo M; Gómez RM
Biomed Res Int; 2014; 2014():421486. PubMed ID: 24982881
[TBL] [Abstract][Full Text] [Related]
9. Experimental vaccines in animal models for schistosomiasis.
Siddiqui AA; Ahmad G; Damian RT; Kennedy RC
Parasitol Res; 2008 Apr; 102(5):825-33. PubMed ID: 18259777
[TBL] [Abstract][Full Text] [Related]
10. Current status of vaccines for schistosomiasis.
McManus DP; Loukas A
Clin Microbiol Rev; 2008 Jan; 21(1):225-42. PubMed ID: 18202444
[TBL] [Abstract][Full Text] [Related]
11. Heteropentameric cholera toxin B subunit chimeric molecules genetically fused to a vaccine antigen induce systemic and mucosal immune responses: a potential new strategy to target recombinant vaccine antigens to mucosal immune systems.
Harakuni T; Sugawa H; Komesu A; Tadano M; Arakawa T
Infect Immun; 2005 Sep; 73(9):5654-65. PubMed ID: 16113283
[TBL] [Abstract][Full Text] [Related]
12. Intradermal immunization of mice with cholera toxin B-pneumococcal surface protein A fusion protein is protective against intraperitoneal challenge with Streptococcus pneumoniae.
Arêas AP; Oliveira ML; Miyaji EN; Leite LC; Ho PL
Infect Immun; 2005 Jun; 73(6):3810-3. PubMed ID: 15908419
[No Abstract] [Full Text] [Related]
13. Intranasal administration of a Schistosoma mansoni glutathione S-transferase-cholera toxoid conjugate vaccine evokes antiparasitic and antipathological immunity in mice.
Sun JB; Mielcarek N; Lakew M; Grzych JM; Capron A; Holmgren J; Czerkinsky C
J Immunol; 1999 Jul; 163(2):1045-52. PubMed ID: 10395703
[TBL] [Abstract][Full Text] [Related]
14. Nasal administration of Schistosoma mansoni egg antigen-cholera B subunit conjugate suppresses hepatic granuloma formation and reduces mortality in S. mansoni-infected mice.
Sun JB; Stadecker MJ; Mielcarek N; Lakew M; Li BL; Hernandez HJ; Czerkinsky C; Holmgren J
Scand J Immunol; 2001 Nov; 54(5):440-7. PubMed ID: 11696194
[TBL] [Abstract][Full Text] [Related]
15. Schistosoma mansoni ex vivo lung-stage larvae excretory-secretory antigens as vaccine candidates against schistosomiasis.
El Ridi R; Tallima H
Vaccine; 2009 Jan; 27(5):666-73. PubMed ID: 19056448
[TBL] [Abstract][Full Text] [Related]
16. Plant cell factories and mucosal vaccines.
Walmsley AM; Arntzen CJ
Curr Opin Biotechnol; 2003 Apr; 14(2):145-50. PubMed ID: 12732315
[TBL] [Abstract][Full Text] [Related]
17. Synthetic peptide vaccines for schistosomiasis.
Harn DA; Reynolds SR; Chikunguwo S; Furlong S; Dahl C
Pharm Biotechnol; 1995; 6():891-905. PubMed ID: 7551254
[No Abstract] [Full Text] [Related]
18. A mucosally administered recombinant fusion protein vaccine against schistosomiasis protecting against immunopathology and infection.
Lebens M; Sun JB; Sadeghi H; Bäckström M; Olsson I; Mielcarek N; Li BL; Capron A; Czerkinsky C; Holmgren J
Vaccine; 2003 Jan; 21(5-6):514-20. PubMed ID: 12531651
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
